Termeer Joins Verastem Board

Xconomy Boston — 

Henri Termeer, the former CEO of Cambridge, MA-based Genzyme, has joined the board of Verastem, a startup seeking to develop treatments against cancer stem cells. Verastem, co-founded by MIT biologists Robert Weinberg and Eric Lander, raised $16 million last November, in a round that included Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners, and MPM Capital. “We believe that Henri’s extensive experience and expertise, gained from building Genzyme into a leading global biotechnology company, will serve as an invaluable asset for Verastem,” said chairman Christoph Westphal, in a statement.